- Details
- Eugene Pietzak, MD, Assistant Attending Surgeon of Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York City received one of the five 2021 Bladder Cancer Advocacy Network (BCAN) New Discoveries Young Investigator Awards for his work in “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.” There are relatively well-established molecul...
|
- Details
- Ashish Kamat hosts Manjiri Dighe for a discussion on the evolving role of radiology in bladder cancer diagnosis and staging. Dr. Dighe elaborates on the limitations and advancements in imaging techniques like CT scans, MRI, and ultrasound, emphasizing their increasing importance for assessing local tumor invasion and lymph node spread. The conversation also delves into the potential of newer metho...
|
- Details
- Svetlana Avulova, MD, Urologic Oncology Fellow at Mayo Clinic received the 2021 BCAN New Discoveries Young Investigator Award for Patient-Centered Research. In this conversation with Ashish Kamat, MD she highlights her project titled “Sexual Function in Women Undergoing Radical Cystectomy”. There is a lack of research on women's quality of life, specifically, on the effect of radical cystectomy on...
|
- Details
- In this conversation with Alicia Morgans, MD, MPH, Arjun Balar, MD highlights a multicenter study first designed in 2014 of gemcitabine hypofractionated radiation therapy and pembrolizumab all in combination as bladder-sparing therapy for patients with muscle-invasive bladder cancer that had a total of 54 patients. The goal of the study was to test the role of immunotherapy pembrolizumab added to...
|
- Details
- With the oncological safety of TURBT unknown, staging inaccuracies are commonplace, and correct treatment of muscle-invasive bladder cancer is potentially delayed. The BladderPath study is looking at using a multiparametric magnetic resonance imaging (mpMRI) scan to diagnose bladder cancer that has grown into the muscle. Drs. Jim Catto and Gary Steinberg join Dr. Ashish Kamat in a discussion about...
|
- Details
- Ashish Kamat hosts Janet Kukreja to discuss intravesical therapy for bladder cancer, providing a comprehensive overview of treatments such as BCG, gemcitabine, and mitomycin C. Dr. Kukreja emphasizes the importance of understanding patient risk categories and adhering to guidelines for treatment decisions. She addresses the ongoing BCG shortage in the U.S., discussing its impact on both treatment...
|
- Details
- In this discussion, Steven Boorjian and Kevin Wymer provide an insightful analysis on the cost-effectiveness of pembrolizumab for BCG-unresponsive carcinoma in situ of the bladder. Given its promising oncologic benefits but high cost and toxicity levels, they conduct a cost-effectiveness analysis comparing pembrolizumab, radical cystectomy, and salvage intravesical chemotherapy. Adopting an ICER (...
|
- Details
- John Sfakianos and Amir Horowitz join Ashish Kamat discussing a novel immune checkpoint axis in non-muscle-invasive bladder cancer, specifically looking at the HLA-E and NKG2A axis in non-muscle invasive bladder cancer, as it relates to Bacillus Calmette-Guerin (BCG) and BCG resistance. Biographies: Amir Horowitz, Ph.D., is an Assistant Professor of Oncological Sciences and a member of the Precisi...
|
- Details
- Joining Ashish Kamat from the Moffit Cancer Center in Tampa, Florida is Roger Li to dive into all things BCG unresponsive bladder cancer. Dr. Li shares what is known about BCG unresponsive disease, some of the conundrums that clinicians and the FDA are challenged by when evaluating and designing clinical trials in this area, and answers a series of questions from Dr. Kamat covering many topics in...
|
- Details
- Eugene Pietzak, MD joins Ashish Kamat, MD MBBS, to discuss an investigator-initiated trial, "Combination BCG and Intravesical Gemcitabine (CBIG) in Patients with BCG Relapsing Non-Muscle Invasive Bladder Cancer" (NCT04179162) that is currently recruiting. Dr. Pietzak explains the rationale for the trial design and the background on the questions this trial seeks to understand, in the combination o...
|
